May 24, 2021 -- Therapeutic Solutions International has filed a patent for data that show a positive combined effect between its tumor blood vessel killing vaccine, StemVacs-V inducible pluripotent stem cell (iPSC), and particular immunological adjuvants.
StemVacs-V iPSC "is a cellular product generated from an inducible pluripotent stem cell (iPSC) which is differentiated into cells that resemble blood vessels which feed the tumor," the company said. The vaccine expresses the alpha1,3-galactosyltransferase gene, resulting in the potent expression of alpha Gal, a powerful immune stimulating molecule.
Therapeutic Solutions also plans to send the data to the U.S. Food and Drug Administration as part of an investigational new drug application.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
